Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.

× No keyword cloud information.

10 in total

Review 1. Pancreatic cancer.

Authors: Manuel Hidalgo
Journal: N Engl J Med Date: 2010-04-29 Impact factor: 91.245

Review 2. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors: Ting-Chao Chou
Journal: Pharmacol Rev Date: 2006-09 Impact factor: 25.468

Review 3. Cell cycle kinases as therapeutic targets for cancer.

Authors: Silvia Lapenna; Antonio Giordano
Journal: Nat Rev Drug Discov Date: 2009-07 Impact factor: 84.694

4. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).

Authors: Ren Nishio; Hiroyuki Tsuchiya; Toshihiro Yasui; Shizuka Matsuura; Keita Kanki; Akihiro Kurimasa; Ichiro Hisatome; Goshi Shiota
Journal: Cancer Sci Date: 2011-01-20 Impact factor: 6.716

5. Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.

Authors: Young Bin Hong; Jung Soon Kim; Yong Weon Yi; Yeon-Sun Seong; Insoo Bae
Journal: Pancreas Date: 2012-04 Impact factor: 3.327

6. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.

Authors: Mark S Duxbury; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal: Clin Cancer Res Date: 2004-04-01 Impact factor: 12.531

7. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.

Authors: A Azzariti; G Bocci; L Porcelli; A Fioravanti; P Sini; G M Simone; A E Quatrale; P Chiarappa; A Mangia; S Sebastian; D Del Bufalo; M Del Tacca; A Paradiso
Journal: Br J Cancer Date: 2011-02-08 Impact factor: 7.640

8. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Authors: David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses
Journal: J Transl Med Date: 2009-06-11 Impact factor: 5.531

9. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.

Authors: Shadi Mamaghani; Satish Patel; David W Hedley
Journal: BMC Cancer Date: 2009-04-30 Impact factor: 4.430

10. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.

Authors: M G Schlieman; B N Fahy; R Ramsamooj; L Beckett; R J Bold
Journal: Br J Cancer Date: 2003-12-01 Impact factor: 7.640

10 in total

3 in total

Review 1. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

Authors: Cyril Ronco; Anthony R Martin; Luc Demange; Rachid Benhida
Journal: Medchemcomm Date: 2016-11-30 Impact factor: 3.597

2. Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.

Authors: Hong-Quan Duong; Yong Weon Yi; Hyo Jin Kang; Insoo Bae; Young-Joo Jang; Sahng-June Kwak; Yeon-Sun Seong
Journal: Int J Oncol Date: 2014-03-21 Impact factor: 5.650

3. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.

Authors: Hong-Quan Duong; Young Bin Hong; Jung Soon Kim; Hee-Seok Lee; Yong Weon Yi; Yeon Jeong Kim; Antai Wang; Wenjing Zhao; Chi Heum Cho; Yeon-Sun Seong; Insoo Bae
Journal: J Cell Mol Med Date: 2013-07-16 Impact factor: 5.310

3 in total